Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rosiglitazone and cardiovascular risk.

× No keyword cloud information.

13 in total

1. Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.

Authors: Brian R Hoffmann; Mohamed F El-Mansy; Daniel S Sem; Andrew S Greene
Journal: J Med Chem Date: 2012-09-28 Impact factor: 7.446

2. Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines.

Authors: Xishan Xiong; Yangliang Ye; Lili Fu; Bing Dai; Jieqiong Liu; Jieshuang Jia; Jing Tang; Lin Li; Li Wang; Jianhua Shen; Changlin Mei
Journal: Invest New Drugs Date: 2008-08-13 Impact factor: 3.850

3. Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents.

Authors: Xishan Xiong; Li Wang; Yangliang Ye; Lili Fu; Minli Chen; Qingyi Wang; Moyan Liu; Jing Tang; Bing Dai; Jianhua Shen; Changlin Mei
Journal: Invest New Drugs Date: 2009-06-17 Impact factor: 3.850

4. DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling.

Authors: Moyan Liu; Lili Fu; Chunyan Liu; Xishan Xiong; Xiang Gao; Min Xiao; Houan Cai; Huimin Hu; Xueqi Wang; Changlin Mei
Journal: Invest New Drugs Date: 2009-09-16 Impact factor: 3.850

5. Association between serious ischemic cardiac outcomes and medications used to treat diabetes.

Authors: David J Margolis; Ole Hoffstad; Brian L Strom
Journal: Pharmacoepidemiol Drug Saf Date: 2008-08 Impact factor: 2.890

Review 6. Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing?

Authors: Edoardo Mannucci; Matteo Monami
Journal: Curr Diab Rep Date: 2009-10 Impact factor: 4.810

7. Impact of rosiglitazone meta-analysis on use of glucose-lowering medications.

Authors: Richard L Morrow; Greg Carney; James M Wright; Ken Bassett; Jenny Sutherland; Colin R Dormuth
Journal: Open Med Date: 2010-03-16

8. Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches.

Authors: Jan O Friedrich; Joseph Beyene; Neill K J Adhikari
Journal: BMC Res Notes Date: 2009-01-10

9. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.

Authors: David N Juurlink; Tara Gomes; Lorraine L Lipscombe; Peter C Austin; Janet E Hux; Muhammad M Mamdani
Journal: BMJ Date: 2009-08-18

10. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials.

Authors: Matteo Monami; Caterina Lamanna; Niccolò Marchionni; Edoardo Mannucci
Journal: Diabetes Care Date: 2008-03-28 Impact factor: 19.112